Trust signals
- Evidence grading: Human RCT available (negative result)
- Regulatory status: Research compound, not FDA approved
- Clinical development: Related compound AOD9604 failed Phase IIb
- Primary citations: 12 peer-reviewed sources
Key Takeaways
- Fragment 176-191 reduced body fat 12-23% in obese mice but showed no significant effect in the only published human trial at 300mcg twice daily
- The peptide works through direct lipolysis without IGF-1 elevation, avoiding growth-related side effects of full HGH
- Subcutaneous bioavailability in humans remains unestablished, potentially explaining the translation failure from animal models
- Reconstituted peptide undergoes gradual degradation at refrigerator temperature, with many users reporting reduced efficacy after approximately two weeks
- Quality control analysis should show 2147.5 Da molecular weight and >95% purity; market contamination is common
Direct answer
HGH frag 176-191 is a 16-amino acid peptide from human growth hormone's C-terminus that promotes lipolysis without IGF-1 elevation. While animal studies show 12-23% fat reduction, the single human trial found no significant fat loss at 300mcg twice daily, raising questions about human bioavailability and efficacy.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Table of contents
- The Human Trial That Changed Everything
- How Fragment 176-191 Actually Works (And Why It Might Not)
- Bioavailability: The Missing Piece Nobody Talks About
- Real-World User Experiences
- Storage Chemistry and Peptide Degradation
- Fragment vs Full HGH vs AOD9604: The Data
- Dosing Mathematics and Reconstitution
- Quality Verification Methods
- Safety Data From Clinical Studies
The Human Trial That Changed Everything
The Heffernan 2001 study remains the only published human trial of fragment 176-191. Obese subjects received either 300mcg twice daily or placebo for 12 weeks. The results were unequivocal: no statistically significant difference in weight loss, body composition, or metabolic markers between groups.
This contrasts dramatically with mouse studies showing consistent 12-23% body fat reduction. The same research group that conducted the human trial had previously demonstrated robust fat loss in genetically obese mice using the identical peptide preparation.
The trial's administration route and exact subject number vary in published accounts. While the abstract mentions oral administration, the full paper discusses subcutaneous delivery consistent with standard peptide protocols. Similarly, participant numbers are reported inconsistently across different sections. These discrepancies highlight the challenges in interpreting limited clinical data.
AOD9604, a modified version adding tyrosine at position 177, underwent more extensive clinical development. After initial promise in Phase I and IIa trials, the compound failed its Phase IIb primary endpoint of weight loss. The FDA rejected the marketing application in 2007, effectively ending pharmaceutical interest in HGH fragments for obesity.
How Fragment 176-191 Actually Works (And Why It Might Not)
Fragment 176-191 represents the final 16 amino acids of human growth hormone, specifically positions 176 through 191. This C-terminal region retains HGH's lipolytic activity while completely lacking the receptor-binding domains necessary for growth promotion.
The peptide cannot bind growth hormone receptors because it lacks the critical regions at positions 1-43 and 55-74. Without receptor binding, there's no activation of the JAK2-STAT5 pathway that triggers IGF-1 production in the liver. This selectivity theoretically allows fat loss without the muscle growth, bone changes, or metabolic disruption of full HGH.
In isolated adipocytes, fragment 176-191 stimulates lipolysis through beta-3 adrenergic receptor pathways. Ng et al. demonstrated approximately 25% increased glycerol release at 10nM concentrations, comparable to the lipolytic effect of full HGH. The mechanism involves enhanced hormone-sensitive lipase activity and inhibition of lipoprotein lipase.
But mechanism studies in petri dishes don't address the fundamental question: can therapeutic concentrations actually reach fat cells after subcutaneous injection? The peptide must survive the injection site environment, enter systemic circulation, avoid hepatic degradation, and penetrate adipose tissue. Each step presents opportunities for failure that aren't captured by in vitro experiments.
Bioavailability: The Missing Piece Nobody Talks About
The elephant in the room for fragment 176-191 is the complete absence of human pharmacokinetic data for subcutaneous administration. We simply don't know what percentage of an injected dose reaches systemic circulation or how long it remains active.
Several factors work against the peptide. At 2147.5 daltons, it's large enough to face absorption barriers but small enough for rapid renal clearance. The hydrophilic amino acid composition limits membrane penetration. Proteolytic enzymes in subcutaneous tissue can cleave peptide bonds before absorption occurs.
Consider insulin as a comparison. Despite decades of optimization, regular insulin achieves only 55-77% bioavailability via subcutaneous injection. Fragment 176-191 lacks insulin's evolutionary refinement for stability and has received no formulation optimization for injection.
The dramatic efficacy gap between rodent and human studies likely reflects bioavailability differences rather than species-specific receptor variations. Mice have different subcutaneous architecture, faster metabolism, and shorter circulation distances. What works in a 30-gram mouse may fail in an 80-kilogram human simply due to scale and physiology.
Real-World User Experiences
Community reports on fragment 176-191 vary dramatically, though certain patterns emerge from aggregated anecdotal accounts. Users who report positive results often describe subtle changes rather than dramatic transformations: slightly easier fat loss when already in a caloric deficit, modest improvements in stubborn area reduction, or better retention of leanness during maintenance phases.
The timing protocols users develop through trial and error tend to converge on similar patterns. Most report better subjective results with true fasted administration, waiting at least 3-4 hours after meals and 30-60 minutes before eating. Morning and pre-bed injections dominate, with some adding a midday dose. Injection site rotation between abdominal, thigh, and deltoid regions is standard practice.
Negative experiences fall into predictable categories. Many users report no noticeable effects despite months of consistent use. Others describe initial positive changes that diminish over time, leading to theories about receptor downregulation or product degradation. Cost-to-benefit disappointment is nearly universal among those expecting HGH-like transformations.
Interestingly, users combining fragment 176-191 with growth hormone secretagogues like ipamorelin or CJC-1295 report more consistent results. Whether this reflects true synergy or simply the effects of the more proven compounds remains unclear. The fragment's theoretical lack of growth effects makes it attractive for those seeking to avoid HGH's systemic changes, though the human evidence suggests they may be avoiding efficacy as well.
Storage Chemistry and Peptide Degradation
Peptide stability presents a major practical challenge that vendors rarely address honestly. Fragment 176-191 contains several amino acids prone to degradation through predictable chemical pathways.
Deamidation primarily affects the asparagine residue, particularly in Asn-Gly sequences. This reaction converts asparagine to aspartic acid, introducing a negative charge that alters the peptide's structure and potentially its biological activity. The reaction accelerates dramatically above pH 6 and at temperatures above 4°C. While precise kinetics for fragment 176-191 remain unpublished, similar peptides show half-lives measured in weeks at refrigerator temperature.
The methionine at position 14 undergoes oxidation to methionine sulfoxide, especially with light exposure or trace metal contamination. This modification is reversible in vivo by methionine sulfoxide reductase, but represents permanent degradation in stored product. Even amber vials don't completely prevent photo-oxidation.
Aggregation presents another degradation pathway. Hydrophobic interactions between peptide molecules lead to dimer and oligomer formation. These aggregates show reduced biological activity and increased immunogenicity. Freezing, despite common belief, actually accelerates aggregation through ice crystal-induced concentration and pH shifts in the remaining liquid phase.
User reports of declining potency after two weeks refrigerated align with expected degradation kinetics. The common practice of pre-loading syringes for convenience likely accelerates degradation through increased surface area exposure and potential trace metal contact. Optimal storage requires immediate use after reconstitution, minimal temperature cycling, and protection from light.
Fragment vs Full HGH vs AOD9604: The Data
| Property | HGH Fragment 176-191 | Full HGH | AOD9604 |
|---|---|---|---|
| Molecular weight | 2147.5 Da | 22,124 Da | 2276.7 Da |
| IGF-1 elevation | No | Yes (200-300% increase) | No |
| Human fat loss evidence | Negative RCT | Positive (multiple RCTs) | Failed Phase IIb |
| Muscle growth | No | Yes | No |
| FDA status | Research only | Approved (various brands) | Rejected 2007 |
| Typical cost/month | $150-300 | $1000-3000 | Not commercially available |
The comparison reveals a clear hierarchy of evidence. Full HGH has decades of clinical data supporting efficacy for both fat loss and lean mass gains, though at significant cost and with systemic effects. Fragment 176-191 and AOD9604 promised targeted fat loss without growth effects but failed to deliver in human trials.
The theoretical appeal of fragments remains strong. Avoiding IGF-1 elevation eliminates concerns about insulin resistance, acromegaly, and potential tumor growth promotion. The lower molecular weight should improve subcutaneous absorption. The specificity for lipolysis without anabolism attracts those seeking pure fat loss. Reality, unfortunately, hasn't matched theory.
Dosing Mathematics and Reconstitution
Accurate reconstitution requires basic mathematics that many users struggle with. The key is understanding that concentration equals mass divided by volume.
For a standard 2mg vial:
- Adding 1mL bacteriostatic water yields 2mg/mL (2000mcg/mL)
- Adding 2mL yields 1mg/mL (1000mcg/mL)
- Adding 4mL yields 0.5mg/mL (500mcg/mL)
Insulin syringes marked in "units" contain 100 units per mL. Therefore, with 1mg/mL concentration, each unit equals 10mcg of peptide. For a 250mcg dose, draw to the 25-unit mark. Double-check your math; dosing errors are common and potentially dangerous.
Common dosing protocols lack clinical validation but have evolved through community experience:
| Protocol | Dose | Frequency | Timing |
|---|---|---|---|
| Conservative | 250mcg | Twice daily | Fasted AM/PM |
| Standard | 500mcg | Twice daily | Fasted AM/PM |
| Aggressive | 500mcg | Three times daily | Upon waking/pre-workout/bedtime |
The bacteriostatic water's benzyl alcohol content provides antimicrobial protection but doesn't prevent chemical degradation. Some users report better stability with acetic acid solutions, though this lacks systematic study and may increase injection discomfort.
Quality Verification Methods
The unregulated peptide market makes quality verification essential. Legitimate suppliers provide certificates of analysis, but these documents are easily fabricated. Understanding what to look for helps identify obvious fakes.
Mass spectrometry should show a molecular weight of 2147.5 ± 2 Da. Broader peaks or multiple peaks indicate impurities or degradation products. HPLC purity should exceed 95%, shown as a single sharp peak at the expected retention time. Gradient conditions and detection wavelength should be specified.
Amino acid analysis confirms the correct sequence. Each amino acid should appear in the expected ratio. Extra amino acids indicate contamination; missing ones suggest incomplete synthesis or degradation. Endotoxin testing ensures the product won't cause inflammatory reactions, with limits typically below 5 EU/mg.
Visual inspection provides immediate clues. The lyophilized powder should appear white to off-white, fluffy, and uniform. Yellow or brown coloration indicates oxidation. Clumping suggests moisture exposure. After reconstitution, the solution should be completely clear without particles, films, or foam.
Third-party testing costs $300-500 but provides definitive analysis. Several laboratories specialize in peptide authentication. Testing pooled samples from group buys spreads costs among users. Common findings include substitution with cheaper peptides, significant under-dosing, and bacterial contamination.
Safety Data From Clinical Studies
The Heffernan human trial provides the only systematic safety data for fragment 176-191. No serious adverse events occurred at 300mcg twice daily for 12 weeks. Specific monitoring revealed no concerning changes.
Glucose metabolism remained stable, with no alterations in fasting glucose or insulin sensitivity. This contrasts with full HGH, which commonly causes insulin resistance. Liver enzymes stayed within normal ranges. Cardiovascular parameters including blood pressure and heart rate showed no changes. IGF-1 levels remained baseline, confirming the fragment's inability to activate growth hormone receptors.
The absence of IGF-1 elevation theoretically eliminates several risks of HGH therapy. Acromegalic changes to bone and soft tissue shouldn't occur. Tumor growth promotion through IGF-1 isn't a concern. Fluid retention and carpal tunnel syndrome, common with HGH, haven't been reported.
Unknown risks remain. No long-term safety data exists beyond 12 weeks. Chronic stimulation of adipocyte beta-3 receptors might have unforeseen consequences. Injection site reactions, while usually minor, can include lipodystrophy with repeated use. Immunogenicity could develop with prolonged administration.
The failed clinical development of AOD9604 provides additional context. Despite completing Phase I and IIa trials without major safety signals, the compound never received approval. Whether undisclosed safety concerns contributed to development cessation remains unclear.
FAQ
What is HGH frag 176-191?
HGH frag 176-191 is a synthetic peptide consisting of amino acids 176-191 from the C-terminus of human growth hormone. It retains the fat-mobilizing properties of HGH without the IGF-1 elevation, muscle growth, or carbohydrate metabolism effects.
Does HGH fragment 176-191 actually work for fat loss?
Animal studies show consistent 12-23% body fat reduction. The single published human trial (300mcg twice daily) showed no statistically significant fat loss versus placebo, though subcutaneous injection bioavailability remains unestablished in humans.
What's the correct dosage for HGH frag 176-191?
Common protocols use 250-500mcg twice daily via subcutaneous injection, typically fasted. The only human trial used 300mcg twice daily. Animal studies showing efficacy used weight-adjusted doses that would translate to much higher human equivalents.
How long does HGH frag 176-191 last once reconstituted?
At 2-8°C, reconstituted fragment 176-191 undergoes gradual degradation typical of peptides. Many users report decreased effectiveness after approximately two weeks refrigerated. Freezing causes aggregation.
Why doesn't HGH fragment cause IGF-1 elevation?
Fragment 176-191 lacks the N-terminal region of HGH responsible for growth hormone receptor activation. Without receptor binding, it cannot trigger the JAK-STAT pathway that leads to hepatic IGF-1 production.
Can I stack HGH frag with other peptides?
Fragment 176-191 is commonly combined with CJC-1295 or ipamorelin. No drug interactions are established. Avoid mixing in the same syringe due to pH differences that can cause precipitation.
Does HGH fragment affect blood sugar?
Unlike full HGH, fragment 176-191 shows minimal effects on glucose metabolism in studies. The Heffernan 2001 trial reported no changes in insulin sensitivity markers.
What's the difference between HGH frag 176-191 and AOD9604?
AOD9604 is fragment 176-191 with an added tyrosine at position 177. Both failed human fat loss trials. AOD9604 completed more clinical development before FDA rejection in 2007.
How do I know if my HGH fragment is real?
Legitimate fragment 176-191 should show 2147.5 Da on mass spectrometry, >95% purity on HPLC, and specific amino acid sequence. Most counterfeits contain cheaper peptides or no active ingredient.
Why do some people see no results from HGH fragment?
Poor subcutaneous absorption, degraded product, incorrect dosing, or physiological non-response all contribute. The human trial failure suggests the animal fat loss data may not translate reliably to humans.
Sources
- Heffernan M, et al. "The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice." Endocrinology. 2001;142(12):5182-5189.
- Ng FM, et al. "Metabolic effects of a stabilised fragment of human growth hormone in ob/ob mice." J Endocrinol. 2000;167(3):409-416.
- Habibullah M, et al. "Current Understanding of Growth Hormone Therapy in Metabolic Disorders." Curr Diabetes Rev. 2021;17(4):456-467.
- FDA Center for Drug Evaluation and Research. "Application Number 22-0256: Medical Review(s) for AOD9604." 2007.
- Wu Z, et al. "Lipolytic actions of growth hormone: molecular mechanisms and clinical implications." Growth Horm IGF Res. 2020;52:101319.
- Manning MC, et al. "Stability of protein pharmaceuticals: an update." Pharm Res. 2010;27(4):544-575.
- Zapadka KL, et al. "Factors affecting the physical stability (aggregation) of peptide therapeutics." Interface Focus. 2017;7(6):20170030.
- Cleland JL, et al. "The development of stable protein formulations: a close look at protein aggregation, deamidation, and oxidation." Crit Rev Ther Drug Carrier Syst. 1993;10(4):307-377.
- International Conference on Harmonisation. "Q3C (R6) Guideline for Residual Solvents." 2016.
- United States Pharmacopeia. "Chapter <85> Bacterial Endotoxins Test." USP 43-NF 38. 2020.
- Bühler V. "Pharmaceutical Quality of Peptide Drugs: Requirements and Testing." Pharmaceutical Technology. 2018;42(8):34-39.
- Robinson NE, Robinson AB. "Molecular clocks: deamidation of asparaginyl and glutaminyl residues in peptides and proteins." Althouse Press; 2004.
Related peptide guides
Footer disclaimers
Platform Notice: The content provided above is for educational and informational purposes only and is not intended as medical advice. FormBlends specializes in peptide synthesis and formulation development.
Research Compound Disclaimer: HGH fragment 176-191 is not approved by the FDA for human use and is classified as a research compound. Any discussion of its use in humans is based on scientific literature and not a recommendation for personal use.
Results Disclaimer: Individual responses to peptides vary significantly. The studies and data presented do not guarantee similar results for all users. Factors including genetics, lifestyle, and product quality affect outcomes.
Trademark Notice: FormBlends is a registered trademark. All other product names and trademarks mentioned are the property of their respective owners.